Form 4: Eli Lilly EVP Acquires Shares Under 10b5-1 Plan

Eli Lilly's EVP & CIDO, Diogo Rau, acquired 4,432.32 shares of common stock at $1,044.67 per share under a pre-arranged 10b5-1 plan.

Summary

• Diogo Rau, Executive Vice President and Chief Information and Digital Officer (EVP & CIDO) of Eli Lilly & Co (LLY), acquired common stock.
• The transaction involved the acquisition of 4,432.32 shares of common stock.
• The acquisition price per share was $1,044.67.
• Following this transaction, Diogo Rau beneficially owns 26,229.69 shares of common stock.
• The transaction was executed on February 9, 2026, and was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an executive's acquisition of shares, even under a 10b5-1 plan, generally indicates confidence in the company's future performance and aligns their interests with shareholders.

Positives

• An executive acquiring shares can signal confidence in the company's future prospects.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary purchase.

Industry Context

StockSavvy.ai notes that insider purchases, especially those under 10b5-1 plans, are common for executives managing their personal portfolios and can sometimes be interpreted as a sign of confidence in the company's long-term value, aligning executive interests with shareholders.

Comparison to Industry Standards

• Insider transactions like this are standard practice across the pharmaceutical industry, with executives at companies such as Pfizer, Merck, and Johnson & Johnson regularly reporting similar stock acquisitions or dispositions under 10b5-1 plans.
• The specific volume and value of shares acquired by Diogo Rau are significant, reflecting a substantial personal investment in Eli Lilly, comparable to high-value insider transactions seen in other large-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal of management confidence in the company's future.

Key Dates

Recommendation

The acquisition of shares by a key executive, Diogo Rau, signals management's confidence in Eli Lilly's future. However, this single insider transaction, while positive, is not sufficient on its own to change a broader investment thesis. It reinforces a 'hold' position for investors who are already invested or considering the stock, as it aligns executive interests with shareholder value without providing new fundamental catalysts.

Keywords

Eli Lilly, LLY, Insider Trading, Form 4, Stock Acquisition, Diogo Rau, 10b5-1 Plan, Executive Stock Purchase